New imaging agent could sharpen detection of blood cancers
NCT ID NCT02128945
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase study tested a new radioactive tracer called [18F]-Fludarabine for PET scans in 10 people with untreated chronic lymphocytic leukemia or diffuse large B-cell lymphoma. The goal was to see how the tracer spreads in the body and how well it highlights cancer cells. If it works, it could offer a more accurate way to image these cancers than the current standard tracer.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- [18F]-Fludarabine (a radioactive tracer for PET scans)
- What this could lead to
- If successful, this could lead to a more accurate PET scan for detecting and monitoring certain blood cancers, especially chronic lymphocytic leukemia.
- What could go wrong
- This is a very early, small study (10 people) focused on safety and imaging, not treatment. The new tracer may not prove better than the current standard scan.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 1
The first testing in people. Mainly checks safety and dose, usually in a small group.
- Participants
-
10 people
The number who actually took part.
- Start date
-
Apr 2014
- Finished
-
May 2016
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Adult over 18 * Signed written informed consent * Untreated stage B or C chronic lymphocytic leukemia * Untreated diffuse large B-cell lymphoma * Eligible for PET-CT * The subject must be covered by a social security system Exclusion Criteria: * Age under 18 * Patients concurrently included in an investigational trial * Weight over 120 kg * pregnant women * active infectious disease * immune hemolytic anemia * patients with creatinine clearance \< 30 ml/mn * corticosteroid therapy
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Diffuse large B-cell lymphoma are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
University Hospital
Caen, 14000, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New drug BL-M08D1 joins standard therapy in fight against aggressive lymphoma
- Can AI spot the lymphoma patients who Won't respond?
- Outpatient immunotherapy tested for hard-to-treat lymphomas
- Can an antibody drug boost standard chemotherapy against an aggressive blood cancer?
- A CAR-T therapy given by injection: can it help Hard-to-Treat lymphoma?
- New drug joins standard chemotherapy in fight against B-Cell lymphoma